T. Quillard (1), K. Croce (1), F. A. Jaffer (2), R. Weissleder (3), P. Libby (1)
(1) Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; (2) Cardiovascular Research Center, Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; (3) Center for Systems Biology and Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
Macrophages contribute pivotally to cardiovascular diseases (CVD), notably to atherosclerosis. Imaging of macrophages in vivo could furnish new tools to advance evaluation of disease and therapies. Proteolytic enzymes serve as key effectors of many macrophage contributions to CVD. Therefore, intravital imaging of protease activity could aid evaluation of the progress and outcome of atherosclerosis, aortic aneurysm formation, or rejection of cardiac allografts. Among the large families of proteases, matrix metalloproteinases (MMPs) and cysteinyl cathepsins have garnered the most interest because of their participation in extracellular matrix remodelling. These considerations have spurred the development of dedicated imaging agents for protease activity detection. Activatable fluorescent probes, radiolabelled inhibitors, and nanoparticles are currently under exploration for this purpose. While some agents and technologies may soon see clinical use, others will require further refinement. Imaging of macrophages and protease activity should provide an important adjunct to understanding pathophysiology in vivo, evaluating the effects of interventions, and ultimately aiding clinical care.
imaging, proteases, macrophage
S. Reuter1, B. Grüner1, A. K. Buck2, N. Blumstein2, P. Kern1, S. N. Reske2
Nuklearmedizin 2008 47 4: 147-152
Bernhard Dorweiler1, Michael Torzewski2, Manfred Dahm1, Charles James Kirkpatrick3, Karl J. Lackner2, Christian-Friedrich Vahl1
Thromb Haemost 2008 99 2: 373-381
P. Falkai, O. Gruber
Die Psychiatrie 2007 4 4: 221-224
Patients receiving oral anticoagulants should be carefully managed to minimize the risk of bleeding...
Acquired haemophilia A (AHA) is a rare but often severe bleeding disorder caused by ...
Section III " Vitamin K antagonists in heart disease: Current status and perspectives" of...